lpath inc-class a (LPTN) Key Developments
Lpath Inc. - Shareholder/Analyst Call
Oct 8 13
To update on plans for iSONEP option
Pfizer Seeks To Divest Certain Ophthalmology R&D Assets
Oct 8 13
Pfizer Limited (BSE:500680) is seeking to divest certain ophthalmology R&D assets. Lpath Inc. (NasdaqCM:LPTN) has received notice from Pfizer Inc. is currently seeking to divest certain ophthalmology R&D assets, including Pfizer's exclusive option for a worldwide license to develop and commercialize Lpath's iSONEP. Lpath has presented an offer to Pfizer to reacquire these rights, and believes that a number of third parties may have an interest in acquiring these rights as well.
Lpath Seeks Acquisitions
Aug 15 13
Lpath Inc. (NasdaqCM:LPTN) is seeking acquisitions. Lpath intends to use the net proceeds from the sale of the securities for general corporate purposes, including working capital and a portion of the net proceeds to invest in or acquire businesses or technologies that Lpath believe are complementary to Lpath, although Lpath have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus.
Lpath Inc. Amends Articles of Incorporation
Jun 21 13
Lpath Inc. announced that effective on June 19, 2013, the company filed a Certificate of Amendment to Articles of Incorporation to increase the authorized common stock from 28,571,429 shares to 100,000,000 shares. The amendment was approved by the company's stockholders at the annual meeting.
Lpath Inc. Presents at 8th Annual JMP Securities Healthcare Conference, Jul-09-2013 02:30 PM
Jun 11 13
Lpath Inc. Presents at 8th Annual JMP Securities Healthcare Conference, Jul-09-2013 02:30 PM. Venue: The St. Regis Hotel, 2 East 55th Street, New York, NY 10022, United States. Speakers: Scott R. Pancoast, Founder, Chief Executive Officer, President, Director and Member of R & D Advisory Committee.